Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 4/2019

Open Access 01-04-2019 | Symposium-in-Writing Paper

Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation

Authors: Giada Amodio, Joanna Cichy, Patricia Conde, Gianluca Matteoli, Aurélie Moreau, Jordi Ochando, Barbaros H. Oral, Michaela Pekarova, Elizabeth J. Ryan, Johannes Roth, Yahya Sohrabi, Maria-Cristina Cuturi, Silvia Gregori

Published in: Cancer Immunology, Immunotherapy | Issue 4/2019

Login to get access

Abstract

Myeloid cells play a pivotal role in regulating innate and adaptive immune responses. In inflammation, autoimmunity, and after transplantation, myeloid cells have contrasting roles: on the one hand they initiate the immune response, promoting activation and expansion of effector T-cells, and on the other, they counter-regulate inflammation, maintain tissue homeostasis, and promote tolerance. The latter activities are mediated by several myeloid cells including polymorphonuclear neutrophils, macrophages, myeloid-derived suppressor cells, and dendritic cells. Since these cells have been associated with immune suppression and tolerance, they will be further referred to as myeloid regulatory cells (MRCs). In recent years, MRCs have emerged as a therapeutic target or have been regarded as a potential cellular therapeutic product for tolerance induction. However, several open questions must be addressed to enable the therapeutic application of MRCs including: how do they function at the site of inflammation, how to best target these cells to modulate their activities, and how to isolate or to generate pure populations for adoptive cell therapies. In this review, we will give an overview of the current knowledge on MRCs in inflammation, autoimmunity, and transplantation. We will discuss current strategies to target MRCs and to exploit their tolerogenic potential as a cell-based therapy.
Literature
9.
go back to reference Skrzeczynska-Moncznik J, Wlodarczyk A, Zabieglo K, Kapinska-Mrowiecka M, Marewicz E, Dubin A, Potempa J, Cichy J (2012) Secretory leukocyte proteinase inhibitor-competent DNA deposits are potent stimulators of plasmacytoid dendritic cells: implication for psoriasis. J Immunol 189:1611–1617. https://doi.org/10.4049/jimmunol.1103293 CrossRefPubMed Skrzeczynska-Moncznik J, Wlodarczyk A, Zabieglo K, Kapinska-Mrowiecka M, Marewicz E, Dubin A, Potempa J, Cichy J (2012) Secretory leukocyte proteinase inhibitor-competent DNA deposits are potent stimulators of plasmacytoid dendritic cells: implication for psoriasis. J Immunol 189:1611–1617. https://​doi.​org/​10.​4049/​jimmunol.​1103293 CrossRefPubMed
58.
go back to reference Fu F, Thai NL, Li Y, Lu L, Thomson AW, Fung JJ, Qian S (1996) Second-set rejection of mouse liver allografts is dependent on radiation-sensitive nonparenchymal cells of graft bone marrow origin. Transplantation 61:1228–1233CrossRefPubMed Fu F, Thai NL, Li Y, Lu L, Thomson AW, Fung JJ, Qian S (1996) Second-set rejection of mouse liver allografts is dependent on radiation-sensitive nonparenchymal cells of graft bone marrow origin. Transplantation 61:1228–1233CrossRefPubMed
61.
go back to reference Ezzelarab MB, Lu L, Guo H, Zahorchak AF, Shufesky WF, Cooper DK, Morelli AE, Thomson AW (2016) Eomesodermin(lo) CTLA4(hi) alloreactive CD8+ memory T cells are associated with prolonged renal transplant survival induced by regulatory dendritic cell infusion in CTLA4 immunoglobulin-treated nonhuman primates. Transplantation 100:91–102CrossRefPubMedPubMedCentral Ezzelarab MB, Lu L, Guo H, Zahorchak AF, Shufesky WF, Cooper DK, Morelli AE, Thomson AW (2016) Eomesodermin(lo) CTLA4(hi) alloreactive CD8+ memory T cells are associated with prolonged renal transplant survival induced by regulatory dendritic cell infusion in CTLA4 immunoglobulin-treated nonhuman primates. Transplantation 100:91–102CrossRefPubMedPubMedCentral
Metadata
Title
Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation
Authors
Giada Amodio
Joanna Cichy
Patricia Conde
Gianluca Matteoli
Aurélie Moreau
Jordi Ochando
Barbaros H. Oral
Michaela Pekarova
Elizabeth J. Ryan
Johannes Roth
Yahya Sohrabi
Maria-Cristina Cuturi
Silvia Gregori
Publication date
01-04-2019
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 4/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-018-2264-3

Other articles of this Issue 4/2019

Cancer Immunology, Immunotherapy 4/2019 Go to the issue

ACKNOWLEDGEMENT TO REVIEWERS

Acknowledgements

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine